Upstream Bio, Inc.
UPBDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 5, 2026
4wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
How UPB's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Verekitug (UPB-101) | Phase 2 | Chronic Rhinosinusitis With Nasal Polyps | - | - |
Verekitug | Phase 2 | Severe Asthma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Upstream Bio, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Upstream Bio, Inc.'s (UPB) pipeline across Phase 2. Its lead program is Verekitug (UPB-101) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Upstream Bio, Inc.'s next FDA catalyst?→
Upstream Bio, Inc.'s (UPB) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track UPB biotech catalysts?→
Add UPB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Upstream Bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.